PDCD1 and neoplasm: PD-L1’s binding to PD-1, a CD8 T-cell receptor, causes co-inhibitory signaling that, in turn, causes the de-activation of tumor-infiltrating lymphocytes (TILs) and promotes tumor progression [59].